[ad_1]
Palantir easily cleared revenue expectations for its latest quarter in what executives said was validation of the software company’s strategy.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...